The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solution
Ching-Yuan Wu,
Yao-Hsu Yang,
Yu-Shih Lin,
Li-Hsin Shu,
Yu-Ching Cheng,
Hung-Te Liu,
Yin-Yin Lin,
I-Yun Lee,
Wei-Tai Shih,
Pei-Rung Yang,
Ying-Ying Tsai,
Geng-He Chang,
Cheng-Ming Hsu,
Reming-Albert Yeh,
Yu-Huei Wu,
Yu-Heng Wu,
Rou-Chen Shen,
Ming-Shao Tsai
Affiliations
Ching-Yuan Wu
Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan; School of Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan, Taiwan; Corresponding author. Department of Chinese Medicine, Chang Gung Memorial Hospital, Chiayi Branch, No.6, W. Sec., Jiapu Rd., Puzi City, Chiayi County, 613, Taiwan.
Yao-Hsu Yang
Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan; School of Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan
Yu-Shih Lin
Department of Pharmacy, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
Li-Hsin Shu
Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
Yu-Ching Cheng
Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan; Department of Otolaryngology, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
Hung-Te Liu
Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
Yin-Yin Lin
Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
I-Yun Lee
Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
Wei-Tai Shih
Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
Pei-Rung Yang
Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
Ying-Ying Tsai
Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
Geng-He Chang
Department of Otolaryngology, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan; Faculty of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital, Chiayi, Taiwan
Cheng-Ming Hsu
Department of Otolaryngology, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan; Faculty of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan
Reming-Albert Yeh
Department of Otolaryngology, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
Yu-Huei Wu
Department of Biomedical Sciences, Chang Gung University, Taoyuan, Taiwan
Yu-Heng Wu
Department of Electrical Engineering, National Sun Yat-Sen University, Kaohsiung, Taiwan
Rou-Chen Shen
Department of Otolaryngology, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
Ming-Shao Tsai
Department of Otolaryngology, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan; Faculty of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan; Corresponding author. Department of Otolaryngology, Chiayi Chang Gung Memorial Hospital, No.6, W. Sec., Jiapu Rd., Puzi City, Chiayi County, 613, Taiwan.
The Chiehyuan herbal oral protection solution (GB-2) is a herbal mixture commonly utilized in Taiwan for combating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as per traditional Chinese medicine practices. This study assessed the clinical impact of GB-2 through prospective clinical trials. With twice-daily use for a week, GB-2 was shown to diminish the expression of angiotensin-converting enzyme 2 (ACE2) in oral mucosal cells. Moreover, after two weeks of use, it could reduce transmembrane protease, serine 2 (TMRPSS2) expression in these cells. Additionally, in vitro experiments demonstrated that GB-2 lessened the entry efficiency of the Omicron, L452R–D614G, T478K–D614G, and L452R–T478K–D614G variants of the SARS-CoV-2 pseudotyped lentivirus. It also impeded the interaction between ACE2 and the receptor-binding domain (RBD) presenting N501Y–K417N–E484A–G339D–Q493R–G496S–Q498R and L452R–T478K mutations. Glycyrrhizic acid, a major compound in GB-2, also hindered the entry of the Omicron variant (BA.1) of the SARS-CoV-2 pseudotyped lentivirus by obstructing the binding between ACE2 and the RBD presenting the N501Y–K417N–E484A–G339D–Q493R–G496S–Q498R mutation. To sum up, these findings suggest that GB-2 can decrease ACE2 and TMPRSS2 expression in oral mucosal cells. Both glycyrrhizic acid and GB-2 were found to reduce the entry efficiency of the Omicron variant (BA.1) of the SARS-CoV-2 pseudotyped lentivirus and block the binding between ACE2 and the RBD with the N501Y–K417N–E484A–G339D–Q493R–G496S–Q498R mutation. This evidence implies that GB-2 might be a potential candidate for further study as a preventative measure against SARS-CoV-2 infection.